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HLA class II antigens are developmentally regulated, polymorphic, ell surface 
glycoproteins that function as restriction elements in cell-to-cell interactions in
the immune response (1). They are heterodimeric, composed of ~ and 13 chains 
of about 34 and 29 kilodaltons, respectively (2). The HLA-DR /3 chain is 
polymorphic, whereas the DR a chain has little or no polymorphism; both DQ a 
and/3 chains exhibit polymorphism (2). The regions of class II molecules involved 
in the restriction phenomenon are unknown. There are at least three well- 
defined class II antigens, HLA-DR, -DQ (formerly MB/DC/DS), and -DP (for- 
merly SB), each with different ~ and/3 chains. Southern blots made with DR, 
DQ, and DP ~ and 13 cDNA probes uggest that the HLA region contains at least 
twice as many class II genes as are necessary to code for the three well-defined 
dimers (3), but it is not known how many or which of these genes are expressed. 
Class II molecules are present on cells involved in the immune response, including 
B cells, macrophages, and activated T cells. They are also expressed transiently 
on erythroid and granulocytic precursor cells (4) and on nonhematopoietic cells 
(5, 6), suggesting that class II molecules may have a more general role in cell- 
cell interactions in development and, also, that nonlymphoid cells may have 
functional roles in the immune response. In addition to developmentally regu- 
lated expression, class II gene expression is modulated in some cells by agents 
such as 3' interferon (7) and prostaglandins (8). 
One approach to studying questions of major histocompatibility complex 
(MHC) j structure and regulation is to isolate and characterize immunoselected 
mutants (9). We previously isolated a class II regulatory mutant, 6.1.6 (10), 
which appears to have a defect in a positive transactive r gulator of transcription 
of class II genes (11, 12). In the present studies, we have used mutagenesis with 
the alkylating agent ethyl methanesulfonate (EMS) and the anti-HLA-DR3 mon- 
oclonat antibody (mAb) 16.23 (13) to isolate a large number of HLA-DR3 
mutants. To simplify the subsequent analysis, the selection was carried out on a 
previously isolated eletion mutant missing all DR and DQ o~ and/3 genes on one 
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haplotype. Several o f  the mutants isolated were found to have defects in the 
epitope reactive with 16.23. Others  have defects in several di f ferent steps in the 
pathway leading to expression o f  the DR a or  /3 genes, including DR gene 
transcript ion and mRNA processing. These  mutants al lowed us to study various 
aspects o f  the regulat ion of  the class I I  gene expression and the structure o f  class 
II  gene products.  
Mater ia l s  and  Methods  
Cell Lines. Deletion mutants 8.1.6 and 9.28.6 were derived from T5-1, a clonal 
derivative of the B cell line PGLC33H, which is DP4 positive and has the HLA haplotypes 
DQ1, DR1, B27, CW1, A2 and DQ2, DR3, B8, A1 (10). 8.1.6 is an immunosetected 
deletion mutant of T5-1 that has lost the cis specificities DQ1 and DR1 (10). By Southern 
blotting it is missing all DQ and DR genes on the DQ1, DR1, B27, CW1, A2 haplotype 
(3). 9.28.6 is an immunoselected deletion mutant ofT5-1 ; it is missing all HLA specificities 
on the DQ2, DR3, B8, A1 haplotype and, by Southern blotting, all class I, II, and III 
genes on that haplotype (3, 14). The DR null mutant 4.36.84 was derived from 9.28.6 by 
mutagenesis with diepoxy octane and selection with the anti-HLA-DR monomorphic 
antibody, VI. 15 (see Results). 
Antibodies Against HLA Class 1I. mAb 16.23 has been shown in population and family 
studies to be HLA-DR3 specific, but it reacts with some HLA-Dw/DRw6 individuals as 
well (13). mAbs VI.15 (14), HB10A (15), L227 (16), L243 (16), LKT (17), and DA6.147 
(18) are class II monomorphic antibodies that are thought o react with HLA-DR and 
possibly with other class II antigens; further characterization of the class II molecules 
reactive with these antibodies is presented in Results. mAb B7/21.2 reacts with a cell 
surface class II molecule structurally distinct from HLA-DR and -DQ (19); transfection 
experiments have established that it reacts with HLA-DP (20). mAb Genox 3.53 is an 
allospecific antibody recognizing DQ 1 (21). mAbs VI. 15 and L243 react only with dimeric 
HLA-DR, whereas HB10A, L227, and LKT react with dimer as well as with DR /3 
monomer. DA6.147 reacts with HLA-DR and with monomeric DR c~. All mAb were 
concentrated 10-20-fold from hybridoma supernatants by (NH4)~SO4 precipitation. 
Mutagenesis and Mutant Isolation. Cells were mutagenized with 100 ~g/ml EMS for 
24 h, washed, and grown in normal medium for 7 d, then used for selection. Selection 
was by brief exposure to an mAb, followed by complement, followed by cloning as 
previously described (22). 
Quantitative Cell Surface Antibody Binding. This was done as described (14). ~25I-labeled 
protein A or ~25I-]abeled 187.1, which is a rat mAb with specificity for mouse K chains 
(23), were used as second-step reagents. All antibodies were used in saturating amounts. 
Class II Gene Clones. The cDNA probes used encode the entire DR c~ (24) and/3 (25) 
chains. 
Northern and Southern Blot Analysis. These methods have been described (12). Each 
Northern blot was repeated two to three times and the blots shown are representative. 
Densitometry was performed using an Ultrascan densitometer (LKB Instruments, Inc., 
Gaithersburg, MD). The band intensities hown are ratios of the peak height of the 
mutant compared with that of 8.1.6, normalized to the ratio of peak heights of class I 
mRNA. 
Western Blot Analysis. Cell lysates were prepared by solubilizing cells at a concentration 
of 5 X 10 7 cells/ml in 1.5% Nonidet P-40 (NP-40) in 10 mM Tris-HCl, pH 7.8, with 0.2 
mM phenylmethylsulfonylfluoride. Lysates were diluted with an equal volume of 2x 
sodium dodecyl sulfate (SDS) sample buffer (2.5% SDS final) and heated for 2 min at 
100 ° C. In those experiments in which detection of undissociated dimers was desired, the 
sample, containing only 0.2-0.4% SDS, was not boiled. Samples were electrophoresed in 
12% SDS-polyacrylamide g l electrophoresis (PAGE), and then electrophoretically trans- 
ferred to a nitrocellulose filter for 2 h at 50 V; 0.1% SDS was included in the transfer 
buffer. The filter was incubated for 1 h at 4°C with phosphate-buffered saline (PBS) 
containing 25% fetal calf serum (FCS). 
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The filters were reacted for 2 h with saturating amounts of first antibody (HB10A or 
DA6.147, which, respectively, recognize DR /3 and a chains), for 1 h with saturating 
amounts of second antibody (rabbit anti-mouse IgG), and for 1 h with subsaturating 
amounts of 125I-protein A at 106 cpm/ml. Anti-actin antibody was added with the HB10A 
or DA6.147 antibody to provide an internal control for the amount of cell extract in each 
lane. Preliminary experiments e tablished that under these conditions, the band intensities 
were proportional to the amount of antigen in the extract. After each incubation, filters 
were washed three times for 5 min each with 100 ml PBS containing 5% FCS and 0.05% 
NP-40. Autoradiographs were prepared using Kodak X-Omat AR film at -70°C. Densi- 
tometry was performed as for the Northern blots except hat the ratios of band intensities 
of mutant o 8.1.6 were normalized to the ratio of the actin band intensities. 
Results 
Mutant Selection and Screening. A deletion mutant o fT5-1 ,  8.1.6, which had 
lost all the DR and DQ a and /3 genes on the DQ1, DR1, B27, CW1, A2 
haplotype, was chosen as a target cell for selection to simplify the interpretation 
of  HLA-DR protein and mRNA levels in any mutants isolated. After mutagenesis 
of 8.1.6 with EMS, immunoselection was carried out with the HLA-DR3 mAb 
16.23, at two levels, one approximately saturating (stringent selection), and the 
other, less than saturating (relaxed selection) (Table I). Relaxed selection maxi- 
mizes the likelihood that mutants which retain some capacity to bind the selecting 
antibody will survive selection, but it also increases the likelihood that nonmutant 
cells will survive (26). Colonies arising after selection were screened for cell 
surface binding of antibody 16.23 by radioimmune binding assay. Only colonies 
with binding ratios <0.5 were studied further (23 of the 62 tested clones). 
The mutant frequencies for clones with binding ratios <0.5, corrected for 
cloning efficiency, were 1.6 × 10 -4 and 3 × 10 -4 for the stringent and relaxed 
selections, respectively. These mutant frequencies are similar to those of  class I 
mutants induced by comparable xposure to EMS (26). Given the mutant 
frequencies, the probability that any mutant contains more than one mutation 
affecting an HLA-DR gene is equal to the observed mutant frequency multiplied 
by the number of  HLA-DR genes, or ~0.001. 
Surface Binding Patterns of Antibodies 16.23, VL 15, and HB IOA Divide Mutants 
into Two Classes. To define the phenotype of these mutants further, the cell 
TABLE I 
Selection of 16.23 Mutants 
16.23 Anti- No. of surviv- Tube No. body ing colonies 
No. of colonies with bind- 
ing ratios* of: 
<0.1 0.1-0.5 >0.5 
ul 
1 500 21 3 5 8 
2 250 64 6 9 31 
EMS-mutagenized 8.1.6 cells, 5 × 10 s per tube, were immunoselected 
with 16.23 hybridoma supernatant in the volumes hown and with 
complement, and were then cloned as described. 
* Binding ratio was calculated as (cpm bound by surviving clone - cpm 
bound by negative control/(cpm bound by 8.1.6 - cpm bound by 
negative control). For details on the binding assay, see Table II. 
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surface binding of various mAb, including 16.23 and several monomorphic anti- 
HLA-DR antibodies, was examined. 15 mutants were studied in detail. A striking 
feature of these data is that the mutants fall into two distinct, nonoverlapping 
groups with respect to the pattern of cell surface binding of 16.23 and VI.15 
(Table II). One group consists of seven mutants (9.2.3, 9.5.3, 9.10.3, 9.25.3, 
9.26.3, 9.28.3, and 9.29.3), which had markedly reduced or absent 16.23 binding 
but normal or near normal binding of the HLA-DR monomorphic antibody 
VI. 15. We interpret this pattern as indicative of expression on the cell surface 
of a normal quantity of HLA-DR3 antigen, as measured by VI. 15 binding, but 
with an alteration in the epitope recognized by the 16.23 antibody (epitope 
defective). The other broad class consists of eight mutants with parallel reductions 
in binding of 16.23 and VI. 15. The parallel reduction in cell surface binding of 
16.23 and VI.15, as well as studies to be described, indicate that these latter 
mutants have a reduced amount of HLA-DR3 antigen expressed at the cell 
surface (expression defective). Cell surface binding of 16.23, VI.15, and L243 
in expression-defective mutants varied from at or near background (mutant 
9.22.3) to ~40%, close to the upper range of binding considered mutant; the 
binding of H B 10A, another class II monomorphic antibody, paralleled but was 
in most cases somewhat higher than that of VI. 15. 
In contrast to the 16.23 and VI.15 binding, the binding of two other class II 
TABLE II 
Cell Surface Antibody Binding by 16.23 Mutants 
Mutant Antibody binding ratio (x l00)  
clone 16.23 VI.15 L243 HB10A LKT  L227 B7/21.2 
(8.1.6) 0oo) (1oo) (loo) (loo) (loo) (lOO) (loo) 
(6.1.6) 15_+3 8_+3 11_+1 4_+1 12_+4 9_+2 10 
9.2.3 3 73 ND ND ND ND ND 
9.5.3 0 102 ND 65 88 100 ND 
9.10.3 0 73 ND 82 97 101 ND 
9.25.3 0 102 ND ND ND ND ND 
9.26.3 12 t06 ND ND ND ND ND 
9.28.3 0 82 ND ND ND ND ND 
9.29.3 7 97 ND 86 ND ND ND 
9.4.3 9 13 11 34 55 43 117 
9.7.3 28 36 ND 33 ND ND ND 
9.12.3 15 25 20 26 75 58 122 
9.13.3 25 22 ND 29 ND ND ND 
9.15.3 17 20 17 34 55 41 105 
9.20.3 41 31 32 ND ND ND 137 
9.22.3 1 3 0 6 45 50 87 
9.27.3 7 12 ND 24 ND ND ND 
Binding ratio: (cpm bound by mutant - cpm bound by negative control)/(cpm bound by 8.1.6 - 
cpm bound by negative control). The negative control is 6.1.6, a regulatory mutant of T5-1 that has 
a reduction of ~99.5% in expression of class I1 molecules (10, 12). Binding ratio of 6.1,6 (cpm bound 
by 6.1.6)/(cpm bound by 8.1.6). The binding ratios represent he median values from three or more 
independent assays. The standard errors given for 6.1.6 are representative. The binding to 6.1.6 
reflects nonspecific binding to the assay tubes. 
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monomorphic  antibodies, LKT  and L227, was reduced at most to 40% of the 
parental value in the expression-defective mutants, even in 9.22.3, which had 
>94% reduction in 16.23, VI.15, L243, and HB10A binding. These findings 
suggest that L227 and LKT  might recognize at least two class II surface 
molecules, only one of  which is affected in these mutants. 
mAbs LKT  and L227 Bind to HLA-DP as Well as HLA-DR. The identity of the 
other molecule besides HLA-DR recognized by LKT  and L227 was studied 
using another  set of  mutants derived from T5-1. Mutant 9.28.6 is an immuno- 
selected, hemizygous deletion mutant of  T5-1 that has lost the complete t tLA  
complex on the DR3 side (3, 14). Selection on 9.28.6 with the anti-DR mono- 
morphic antibody VI. 15 yielded the DR null mutant 4.36.84 (Table III); selection 
on 4.36.84 was then carried out with the anti-DP antibody B7/21.2. All three 
mutants from the B7/21.2 selection that are B7/21.2 null (11.6.84, 11.11.84, 
and 11.13.84) also lost LKT  and L227 binding, indicating that loss of LKT  and 
L227 binding is coincident with loss of  HLA-DP.  The  fact that Genox 3.53 
binding was retained in these mutants argues against a deletion extending from 
HLA-DP to -DQ. Thus,  LKT  and L227 must detect a determinant shared by 
DR and DP/3 chains. 
Expression-defective Mutants Have Alterations or Reductions in Either DR 0¢ or t3 
mRNA, But Not in Both. To  investigate the nature of the lesions in mutants with 
reduced levels of HLA-DR3 at the cell surface, Northern blotting with HLA-  
DR c~ and /3 cDNA probes was used to determine levels of DR a and/3 chain 
mRNA.  Representative blots are shown in Figs. 1 and 2. All the expression- 
defective mutants had a clear reduction or alteration in either DR a or/3 mRNA,  
but not in both. Mutants 9.4.3, 9.15.3, 9.16.3, 9.20.3 (and 9.7.3 and 9.13.3, not 
shown) had reductions in DR3/3 mRNA ranging of 70-95%,  whereas their DR 
mRNA levels are essentially normal. Mutant 9.22.3, in contrast, had no 
detectable DR c~ mRNA but had normal levels of DR/3 mRNA.  Mutant 9.12.3 
had a reduced amount  of  DR a mRNA of  normal size (1.2 kilobase [kb]), but, in 
addition, had a second band of  2.7 kb, not seen in 8.1.6 or other mutants, which 
hybridized to the DR a probe. Thus,  in all the mutants that were initially 
TABLE III 
Cell Surface Antibody Binding by HLA-DR and -DR, 
Mutants 
-DP Null 
Mutant Antibody binding ratio (X 100) 
clone B7/21.2 VI. 15 B 10A LKT L227 Genox 
(9.28.6) (100) (100) (100)  (100)  (100) (100) 
(6.1.6) 14 2 4 9 11 14 
4.36.84 128 0 3 40 18 79 
11.6.84 0 0 0 0 1 133 
11.11.84 0 0 0 0 0 62 
11.13.84 0 0 0 0 1 108 
For details on the binding assay, see legend to Table I1. For the origins of 
the DR null mutant 4.36.84, and the DR and DP null mutants 11.6.84, 
11.11.84, and 11.13.84, see Results. 
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FICURE 1. Northern blot analysis of  8.1.6 and mutant  RNAs with DR a and/3 and HLA 
class I cDNA gene probes. The  18 and 28 S ribosomal RNAs can be seen faintly on the DR/3 
blots. The  ratios of  band intensities of  mutants  to 8.1.6 for the DR a and 13 mRNA,  respectively, 
are: 9.4.3, 0.66 and 0.06; 9.15.3, 0.81 and <0.06; 9.16.3, 1.42 and 0.07; 9.20.3, 1.00 and 
0.21; 9.22.3, <0.06 and 0.72. The  alterations in 9.12.3 DR c~ mRNA can be seen more clearly 
in Fig. 2. 
grouped together on the basis of reduced levels of HLA-DR3 protein at the cell 
surface, the reduction can be accounted for by a reduced level or altered size of 
DR ot or/3 mRNA. 
Mutant 9. 22.3 Has a Deletion of the DR a Gene. We investigated the possibility 
that one or more of the expression-defective mutants resulted from gross 
deletions of DR structural genes, which could be detected by Southern blotting 
using DR o~ and/3 cDNA probes. The DR a probe hybridizes to a single gene 
(23) that maps to the HLA class II region (27). A DR o~ Bgl II restriction fragment 
length polymorphism (RFLP) has been described; T5-1 is heterozygous for this 
RFLP, with bands of 4.2 and 3.8 kb (Fig. 3A). 8.1.6 is deleted for DQ1 and 
DR1 and had only the 3.8 kb DR a band. Mutant 9.22.3, derived from 8.1.6, 
lacked both the 4.2 and the 3.8 kb bands and therefore has undergone deletion 
of the remaining DR ~ gene. Southern blots made with the DR 13 probe were 
more complex, because each haplotype carries two r more DR /3 genes, and 
haplotypes may differ with respect to the number of DR /3 genes carried. 
However, we have previously shown (3) that in 8.1.6 all DR/3 genes on the DR 1 
haplotype of T5-1 are deleted; thus, all bands hybridizing to the DR/3 probe in 
8.1.6 come from the DR3 haplotype. Fig. 3B shows that all bands in 8.1.6 
hybridizing with the DR/3 probe were also present in 9.22.3. Thus, the deletion 
in 9.22.3 does not extend to the closely linked DR 13 gene complex, nor to the 
complement C4 gene (data not shown). No bands hybridizing to the DR/3 probe 
were lost in the other DR /3 expression-defective mutants; therefore, of these 
mutants, only 9.22.3 has a deletion large enough to be detected by Southern 
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FIOURE 2. Northern blot analyses of 8.1.6, 9.12.3, and 9.22.3 RNAs with DR a and ~ gene 
probes. The band intensity ratios for 9.12.3 are: DR a 2.7 kb mRNA, 0.31; 1.2 kb mRNA, 
0.28; DR ~ mRNA, 1.13. 
blotting. The  fact that there was essentially no binding of  16.23, VI.15, L243, 
or HB10A to 9.22.3 (Table II), although the deletion did not extend to the DR 
/3 genes, suggests that DR ~3 subunits do not form noncognate dimers with DQ 
or DP a chains. 
Methylation of a Single DR t3 Gene Is Altered in Some DR 13 Expression-defective 
Mutants. Class II genes from cells active in class II gene transcription have 
different patterns of cytosine methylation than those from class II nontranscrib- 
ing cells (28). It was therefore of  interest to determine whether there were 
changes in the patterns of methylation of DR /3 genes in the HLA-DR /3 
expression-defective mutants described here. Southern blots were made from 
Bgl I I -Hpa  II double digests of  DNA from 8.1.6 and from several DR /3 
expression-defective mutants, and were hybridized with a DR /3 cDNA probe 
(Fig. 4). O f  the six strongly hybridizing bands seen in the Bgl I I -Hpa  II double 
digests, five were identical in 8.1.6 and in all three mutants. The  sixth band (5.0 
kb) was present in 8.1.6 and in mutant 9.20.3, but was missing in mutants 9.4.3 
and 9.15.3, and was replaced in 9.4.3 and 9.15.3 by a band of 4.6 kb. Thus, a 
cytosine in or around one of  the DR /3 genes is methylated in 8.1.6, which 
expresses DR /3, but is demethylated in mutants 9.4.3 and 9.15.3, which have 
severe reductions in DR/3 mRNA level. 
Expression-defective Mutants Have Reduced Levels of Both DR a and /3 Protein 
Subunits. The reductions in DR a or /3 mRNA in the expression-defective 
mutants and the cell surface binding data predict that the amounts of  the 
corresponding subunit proteins should also be reduced. To  investigate this, 
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FIGURE 3. Southern blot analysis of 8.1.6 and expression-defective mutants with DR a and 
/3 gene probes. The restriction fragment sizes were calculated from a Hind Ill digest of lambda 
DNA (not shown). 
FIGURE 4. Methylation patterns of DR/3 genes in 8.1.6 and in mutants with reduced DR/3 
mRNA levels. The restriction enzymes Hpa II and Msp l recognize the same sequence (5' 
CCGG 3') but differ in that Hpa II will not cut if the internal cytosine is methylated whereas 
Msp I will cut regardless of the methylation state of the internal cytosine. In the first lane, 
8.1.6 DNA had been digested with Bgl II plus Msp I; in the other lanes the DNAs had been 
digested with Bg! It and Hpa It. 
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detergent extracts of  the cells were boiled and reduced to dissociate the HLA- 
DR dime'r, then subjected to Western blotting using mAbs DA6.147 and HB 10A 
to detect the DR a and 13 subunits, respectively. Fig. 5 shows representative 
Western blots of  detergent extracts from equal numbers of mutant and 8.1.6 
cells. The  most striking finding from these studies is that the quantities of  both 
DR a and/3 chains were decreased in all the mutants that had reduced expression 
of  HLA-DR3 on the cell surface. Even though in each expression-defective 
mutant he defect can be related to a reduced level or alteration in size of  either 
DR 0~ or/3 mRNA, but not of  both, the levels of both DR a and/3 subunits were 
reduced in all. The  fact that all mutants with reductions of  either DR a or/3 
mRNA had reductions in both DR a and /3 protein subunits suggests that the 
protein product from the unaffected DR a or /3 gene must undergo rapid 
degradation unless it can form dimers. The apparently greater eduction in DR 
0~ than /3 subunits in all the expression-defective mutants may reflect affinity 
differences between DA6.147 and HB10A for their respective target antigens. 
The  instability of  HLA-DR protein monomers is in contrast o the stability of  
class I heavy chain monomers, which accumulate intracellularly both in mutants 
with altered heavy chains that are unable to dimerize (26), and in the Daudi cell 
line, which lacks/3z microglobulin (29). 
Epitope-defective Mutants Have Altered Subunit Associations. To  search for 
further evidence of  structural changes in 16.23 epitope mutants, we altered the 
conditions of preparation of the cell sample for Western blots so as to visualize 
the HLA-DR dimer. It is known that HLA-DR antigen migrates as a dimer in 
SDS-polyacryamide g l electrophoresis (SDS-PAGE) if samples are not boiled 
(30). Cell lysates were therefore prepared without prior boiling or reduction, in 
a sample buffer containing 0.2% SDS, and were electrophoresed, blotted, and 
reacted with HB10A according to standard procedures. As shown in Fig. 6, 
about two-thirds of the HB 10A binding in wild-type 8.1.6 cells was to the HLA- 
DR dimer, and the remainder was to the DR/3 monomer.  In contrast, under the 
same conditions no dimer could be seen from any of  the 16.23 epitope mutants, 
and the amount of  DR/3 monomer was increased in proport ion to the reduction 
in dimer. These results indicate that the lesions in the 16.23 epitope mutants 
FIGURE 5. Western blot analyses of DR a and/3 protein subunits in boiled NP-40 extracts of 
expression-defective mutants. The ratios of DR a and/3 band intensities of mutants to 8.1.6, 
normalized to actin, respectively are: 9.4.3, 0.05 and .41; 9.12.3, 0.11 and 0.60; 9.22.3, 
<0.04 and <0.04; 9.29.3, 0.61 and 0.60. 
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FIGURE 6, Western blot analysis of  HLA-DR3 protein dimer and DR t3 monomer in unboiled 
NP-40 extracts of  epitope-defective mutants. 
have reduced the strength of the DR subunit association, rendering the DR3 
dimer more susceptible to dissociation by dilute SDS. However, since cell surface 
binding of the conformation-sensitive antibody VI. 15 is reduced at most by 30% 
in the epitope mutants, the effect of the mutational lesion on HLA-DR3 subunit 
association, transport, or conformation in the intact cell under physiologic 
conditions cannot be large in any of the mutants. The fact that the majority of 
the HB10A binding in the Western blot of 8.1.6 is to dimer whereas, in the 
epitope mutants, no dimer is seen under the same conditions, suggests that most 
of the dimer reactive with HB10A contains the DR/3 chain bearing the 16.23 
epitope; otherwise, dimer that formed with the second, unaltered /3 chain, if 
present in appreciable amounts, should have been apparent in the Western blots 
from the epitope mutants. 
Discussion 
In this report we describe two broad classes of HLA class II mutants, those 
which express relatively normal amounts of HLA-DR3 at the cell surface, but 
with an altered structure, and those which express reduced amounts of HLA- 
DR3. The lesions in the latter, taken together, affect a variety of steps in the 
pathway leading to class II gene expression. Characterization f the lesions in 
these mutants therefore offers an approach to elucidating steps involved in class 
II regulation. We have previously (10-12) described a mutant, 6.1.6, which 
expresses virtually no class II gene products because of a defect in a transactive 
regulator of transcription of all class II genes. The expression-defective mutants 
described here all differ from 6.1.6 in that they only affect expression of HLA- 
DR o~ or/3. Some of the expression-defective mutants have lesions analogous to 
those found in mouse strains that are defective in expression of I-E (31), the 
murine homolog of HLA-DR, whereas others have defects in class II gene 
expression that have not been previously described. 
Among the latter are mutants 9.4.3 and 9.15.3, which have severe reductions 
in HLA-DR3 protein and DR/3 mRNA levels accompanied by demethylation f 
a CpG in one of the DR /3 genes. We have previously noted (28) a strong 
correlation between class II gene nonexpression a d demethylation f CpG sites 
in or around class II genes in isogenic pairs of cells, one of which expresses class 
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II genes and the other of which does not. The demethylation f only one of the 
DR/3 genes in 9.4.3 and 9.15.3 is in contrast o the demethylation seen in all 
class II genes in 6.1.6; it is consistent with the more limited lesions in 9.4.3 and 
9.15.3, which appea~ to affect ranscription of a single DR/3 gene. The selective 
nature of the transcriptional defect in 9.4.3 and 9.15.3, limited to a single DR/3 
gene, makes it likely that the mutational lesions are in an element cis to the 
affected DR /3 gene, rather than in a transactive factor, as in 6.1.6. Such a cis 
lesion might be in a promoter or enhancer. Evidence has recently been obtained 
for an enhancer in the 5' end or flanking region of the I-E/3 gene, the murine 
homolog of DR/3 (32, 33). By sequencing genomic lones of the affected genes 
and the 5' flanking regions of transcription-defective mutants uch as 9.4.3, it 
should be possible to define the cis sequences involved in regulation of transcrip- 
tion of HLA class II genes. 
Whereas the lesions in mutants 9.4.3 and 9.15.3 are at the level of transcrip- 
tion, those in 9.12.3, 9.20.3, and 9.27.3 appear to affect different posttranscrip- 
tionai steps. In the HLA-DR3 mutant 9.12.3, the reduced level of normal DR a 
mRNA and the appearance of a new, larger mRNA species hybridizing to the 
DR o~ probe are most easily explained by a nucleotide substitution that alters the 
processing of the DR a transcript by creating an alternative splice site. These 
alterations in DR a mRNA in 9.12.3 closely resemble those reported by Mathis 
et al. (31) in I-E ~ mRNA from the B10.M strain of mouse. Mutant 9.20.3, which 
has a reduced level of DR/3 mRNA without a change in methylation of DR/3 
genes, appears to have a lesion affecting DR /3 mRNA processing or stability. 
Mutant 9.27.3 has normal levels of DR a and /3 mRNA, but in preliminary 
experiments appears to have reduced levels of DR ot and/3 subunits. These could 
result from a nonsense or cap site mutation or one affecting a posttranslational 
step, such as the association of DR o~ and/3 subunits to form dimers. 
The analysis of mutants uch as those described here offers additional insights 
into issues concerning the class II region. Among these issues are which of the 
several DR/3 genes are expressed, and how specific class II genes are related to 
the specific class II gene products recognized by mAb. Mutant 9.4.3 provides 
information on both the relative quantities of the different DR/3 genes expressed 
per haplotype as well as the gene coding for the gene product recognized by 
antibodies 16.23, L243, and VI.15. Mutant 9.4.3 has a methylation change in 
only one DR/3 gene, and has lost ~94% of the mRNA hybridizing to the DR fl 
probe, indicating that most of the mRNA hybridizing to the DR/3 cDNA gene 
probe is transcribed from one DR/3 gene. The reduction in binding of 16.23, 
VI.15, and L243 in 9.4.3 makes it likely that these antibodies bind only to the 
product of the DR fl gene affected in 9.4.3. On the other hand, antibody HB 10A 
binding is only reduced by two-thirds in 9.4.3; therefore, HB10A reacts with the 
same DR /3 chain as do 16.23, VI.15, and L243, but it also must react with a 
second/3 chain not affected in 9.4.3. The deletion of the DR a gene in 9.22.3 
virtually eliminates HB10A binding; therefore, the second/3 chain reactive with 
HB10A must be a DR fl chain. Assuming that the residual binding of ~10% for 
16.23, VI.15, and L243 on 9.4.3 reflects the remaining expression of the major 
DR fl chain, the second DR/3 chain appears to be only 20% as abundant as the 
major DR fl chain. Unlike binding by the other monomorphic antibodies, LKT 
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and L227 binding are only reduced by 50-60% by the DR a deletion in 9.22.3, 
suggesting that these antibodies react with non-DR as well as DR/3 chains. The 
complete loss of LKT and L227 binding in a DR null mutant hat was subse- 
quently selected for and had lost DP expression indicates that the non-DR /3 
chain to which LKT and L227 bind is HLA-DP. This conclusion concerning 
L227 agrees with that based on studies of deletion mutants (34), but differs from 
that based on immunoprecipitation experiments (35). 
Mutants with single amino acid substitutions in the epitope recognized by the 
antibody used for selection have proven useful in primary sequence mapping of 
an alloepitope of an HLA class I molecule (36, 37) as well as in functional studies 
(38, 39). Comparable class II mutants can be used for similar purposes. The fact 
that 16.23 binding is lost in mutants uch as 9.5.3 whereas VI.15, L243, and 
HB 10A binding remains essentially normal, together with the evidence presented 
above that 16.23, VI.15, and L243 bind to the same molecule, indicates that 
mutants uch as 9.5.3 are in fact epitope defective. A striking feature of the 
epitope-defective mutants i that they all have reductions in the strength of their 
HLA-DR3 subunit associations. One explanation for this similarity among the 
epitope mutants is that they all derive from the same mutational event, but this 
seems unlikely based on the finding of a minimum of five distinct phenotypes in
the eight expression-defective mutants, and on previous data from a comparable 
EMS mutagenesis and HLA-A2 selection, which yielded a minimum of nine 
different phenotypes (including at least four different epitope mutants) of 15 
mutants tudied. If the epitope-defective mutants arose from different events, 
then the fact that all are affected in their HLA-DR3 subunit associations suggests 
two interesting alternatives. Either changes in the several amino acids composing 
the 16.23 epitope have a high likelihood of affecting dimer stability or, con- 
versely, the 16.23 epitope is perturbed by amino acid substitutions broadly 
distributed throughout one or both subunits. 
DNA sequencing of the epitope mutants offers a way of identifying which of 
the several DR ~ genes present on an HLA baplotype is the expressed gene 
bearing the HLA-DR3 epitope recognized by 16.23, and of locating the amino 
acids comprising the epitope. These studies hould contribute to an understand- 
ing of the associations of HLA-DR3 with autoimmune diseases. Recently (40), 
murine alloantibody-selected class II mutants have been found to be altered in 
their ability to present soluble antigen. Human Epstein-Barr virus-transformed 
B cell lines are able to present soluble antigen in a class II-restricted manner 
(41). These mutants thus should provide a means of assessing the effects of 
specific amino acid substitutions in class II molecules on antigen presentation i  
human cells. 
Summary 
Point mutations that affect HLA-DR structure or expression have not previ- 
ously been described. In the present study, we isolated such mutants by immu- 
noselection of an ethyl methanesulfonate-mutagenized HLA-DR3 cell line with 
an anti-HLA-DR3 monoclonal antibody, 16.23. To facilitate analysis, we used a 
parent cell line with a preexisting deletion of one haplotype ncompassing DR 
and DQ o~ and/3. The selection yielded two sets of mutants, one with defects in 
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DR3 structure, the other with defects in different steps leading to DR expression. 
Of  the expression-defective mutants, one had undergone a second deletion 
removing the remaining DR ~ gene but no other class II genes. It had a normal 
abundance of  DR/3 mRNA but had lost binding of DR monomorphic antibodies, 
indicating that DR/3 chains do not form noncognate dimers. A second mutant 
had an abnormally large DR o~ mRNA, probably resulting from a splice site 
mutation. Several mutants had marked reductions in DR fl mRNA levels; in two 
of  these, the lesion appeared to be transcriptional because the reduction in DR 
/3 mRNA was paralleled by an altered methylation pattern of one of the DR/3 
genes. Other  expression-defective mutants had different posttranscriptional de- 
fects. Some of the mutations were similar to those that have been found in mouse 
strains defective in I-E expression, whereas others have no known natural 
counterpart.  The  matrix of  reactivities of  anti-HLA class II monomorphic 
antibodies with these and similar mutants allowed us to define the gene products 
recognized by these antibodies. 
A set of seven mutants were "epitope defective," that is, they expressed normal 
or near normal levels of  HLA-DR3 but no longer bound 16.23. Unexpectedly, 
each of  the epitope mutants had decreased DR dimer stability. These mutants 
should be useful in localizing the DR3 alloepitope and in elucidating its contri- 
bution as a restriction element in the presentation of soluble antigen to immune 
T cells. 
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manuscript. 
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